MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.
MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.
MiniMed Group, a Medtronic spin-off, is rated a buy with an FY 2027 price target of $19, implying 15% upside. MMED's double-digit revenue growth is driven by strong international adoption, expanding CGM attach rates, and timely product launches ahead of schedule. Despite gross margin compression and widened net losses in FY 2026, robust liquidity from IPO proceeds supports ongoing product rollouts and operational improvements.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Chilton Investment Chilton Investment Co Inc. | 232,299 | $3.47M | $5.29M | $1.82M | 52.45% |
Point72 Asset Management LP Point72 Asset Management LP | 15,395 | $229,693.41 | $310,055.3 | $80,361.89 | 34.99% |
Joseph Castro Nuveen LLC | 539,313 | $8.06M | $12.31M | $4.25M | 52.71% |
Regan O'Neill Burkehill Global Management LP | 300,000 | $4.48M | $6.99M | $2.51M | 56.07% |
Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3,282 | $49,066 | $74,698.32 | $25,632.32 | 52.24% |
| Diversified Consumer Services Industry | Consumer Discretionary Sector | Que Thanh Dallara CEO | NASDAQ (NMS) Exchange | 60365F109 CUSIP |
| US Country | 8,000 Employees | - Last Dividend | - Last Split | - IPO Date |
MiniMed Group, Inc. specializes in the development, manufacturing, and marketing of innovative medical devices designed specifically for diabetes management. Established in 1983 by Alfred E. Mann, the company is headquartered in Northridge, California. MiniMed Group focuses on creating solutions that empower individuals with diabetes and their healthcare providers to effectively monitor and regulate blood glucose levels, significantly improving patient outcomes and quality of life.